



COMPANY ANNOUNCEMENT

23 October 2025

No. 15-2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

ViroGates announces Notice of Potential Equity / Capital Raise

BIRKERØD, DENMARK—ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, announces that it intends to explore options to raise additional capital in the near term to support its strategic initiatives, including accelerating growth in the preventative health and longevity markets, advancing regulatory approvals, and expanding its commercial distribution network internationally.

This announcement follows a statement by Supar Remedy, LLC in the Tender Offer document, published in [Company announcement No. 12/2025](#) of 10 October 2025, and the Board of Directors’ Board Statement, published in [Company announcement No. 13/2025 of 15 October 2025](#), acknowledging the need to raise more capital to fund the Company’s operations and strategy for pursuing the broader longevity market.

At this stage, no decision has been made regarding the structure, size, timing, or pricing of any such capital raise. Possible mechanisms under consideration include a rights offering and/or a directed share issue.

Any such transaction would be subject to Board approval, relevant corporate authorizations (including potentially an Extraordinary General Meeting), and market conditions.

Once the various options to raise additional capital have been discussed, and insofar as the Board decides to proceed with a capital raise, the Company will publish an announcement with the details in accordance with applicable rules and regulations.

This announcement is also available [here](#).

For more information, please contact:

Jakob Knudsen
CEO, ViroGates A/S

jk@ViroGates.com
+45 22 26 13 55

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation in health clinics and improve hospital patient care.

ViroGates markets its blood test products under the suPARnostic® brand.

The Company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (ticker "VIRO") are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.